Systemic Inflammatory Response Syndrome Treatment Market (Indication: Meningitis, Urinary Tract Infection (UTI), Pneumonia, Hemorrhage, Autoimmune Diseases, Others; End User: Hospital & Ambulatory Surgical Centers, Specialty Clinics, Others) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2022 - 2030

The global Systemic Inflammatory Response Syndrome Treatment market gathered revenue around USD 11.29 billion in 2021 and market is set to grow USD 21.36 billion by the end of 2030 and is estimated to expand at a modest CAGR of 7.37 % during the prediction period 2022 to 2030

Growth Factors:

Systemic inflammatory response syndrome (SIRS) is defined as a clinical response to a nonspecific onslaught of either infectious or noninfectious origin. SIRS is nonspecific and can be caused by ischemia, inflammation, trauma, infection, or several indications combined. Infection is a major cause of systemic inflammatory response syndrome; however, a number of other indications, including trauma, ARDS, neoplasm, burn injury, pancreatitis, and dysfunctional macrophage activation are also recognized causes.

In terms of indication, the others segment held a major share of the global systemic inflammatory response syndrome treatment market in 2018. The segment is anticipated to dominate the market during the forecast period, owing to increased penetration. Based on end user, the hospitals & ambulatory surgical centers segment is expected to account for a significant share of the global systemic inflammatory response syndrome treatment market. The segment is likely to grow at a rapid pace during the forecast period. The hospitals & ambulatory surgical centers segment is projected to dominate the global market during the forecast period, due to increase in inpatient admissions in hospitals and ambulatory surgical centers. However, limited availability of therapeutics for SIRS and lack of quality care for critically-ill patients are anticipated to hamper the growth of the global SIRS treatment market during the forecast period. 

Report Scope of the Systemic Inflammatory Response Syndrome Treatment Market

Scope of the Report

Introduction of Effective Therapies and Drugs to Catalyze Market Growth

As concerns regarding the gravity of sepsis increase, market players operate within the range of innovation to develop effective drugs and therapeutics. Among other therapies, CytoSorb, a specific extracorporeal cytokine adsorber, is emerging as an effective therapy to reduce inflammation and control the failure of vital organs, such as the lungs, kidneys, heart, and brain. Also, as demand for the initial-stage diagnosis of sepsis becomes more prominent, biomarkers were introduced for early detection, treatment, and disposition of the condition.

Besides therapies, ample efforts backed by central and private funding are leading to the development of numerous pipeline drugs. For instance,

Adrenomed AG introduced Adrecizmab, which is deemed effective for the treatment of septic shock. The drug also holds efficiency in preventing vascular damage and keeping intact ideal vascular functions. Led by efficiency, therapeutics and pipeline drugs are projected to uphold demand in the systemic inflammatory response syndrome treatment market.

Since developed countries remain at the forefront for the development of advanced therapies and drugs, given their sound technical knowledge, partnerships with players in developing countries are seen as a strategic move to gain a reciprocal advantage in the SIRS market. For instance, CytoSorbents Corporation collaborated with Biocon Ltd. to create a huge market for the sales of CytoSorb in overseas territories.

Systemic Inflammatory Response Syndrome Treatment Market: Prominent Regions

North America held a major share of the global systemic inflammatory response syndrome treatment market in 2018. The market in the region is expected to grow at a rapid pace during the forecast period. The market in North America is driven primarily by a rise in the prevalence of SIRS and increase in knowledge about SIRS among healthcare professionals. Additionally, surge in government initiatives toward infectious & non-infectious diseases, increase in the geriatric population that is at high risk, and a large number of players in North America focusing on R&D activities to introduce technologically-advanced systemic inflammatory response syndrome treatments with improved designs propel the market in the region. The systemic inflammatory response syndrome treatment market in Asia Pacific is likely to witness strong growth. Asia Pacific is a relatively untapped market as compared to developed regions. Hence, the region offers immense opportunities to market players. Rise in the prevalence of SIRS, increase in knowledge about SIRS among healthcare professionals, growth of the healthcare industry, and awareness in the region fuel the growth of the SIRS treatment market in the region. 

Europe held the second-largest market share in 2018. Well-developed healthcare infrastructure augments the systemic inflammatory response syndrome treatment market in the region. The markets in the Middle East & Africa and Latin America are projected to witness moderate growth in the near future. 

Some of the prominent players in the Systemic Inflammatory Response Syndrome Treatment Market include:

• CytoSorbents Corporation
• RegeneRx Biopharmaceuticals, Inc.
• Endacea, Inc.
• Adrenomed AG
• GlaxoSmithKline plc
• Asahi Kasei Corporation
• Cardinal Health
• Smith & Nephew plc
• ConvaTec, Inc.
• AstraZeneca
• Orion Corporation
• CHIESI Farmaceutici S.p.A.
• Mylan N.V.

Segments Covered in the Report

This research report offers market revenue, sales volume, production assessment and prognoses by classifying it on the basis of various aspects. Further, this research study investigates market size, production, consumption and its development trends at global, regional, and country level for the period of 2017 to 2030 and covers subsequent region in its scope:

Global Systemic Inflammatory Response Syndrome Treatment Market: Segmentation

Systemic Inflammatory Response Syndrome Treatment Market by Indication

• Meningitis
• Urinary Tract Infection (UTI)
• Pneumonia
• Hemorrhage
• Autoimmune Diseases
• Others

Systemic Inflammatory Response Syndrome Treatment Market by End User

• Hospital & Ambulatory Surgical Centers
• Specialty Clinics
• Others

By Geography

North America

• U.S.
• Canada

Europe

• Germany
• France
• United Kingdom
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Southeast Asia
• Rest of Asia Pacific

Latin America

• Brazil
• Rest of Latin America

Middle East & Africa (MEA)

• GCC
• North Africa
• South Africa
• Rest of Middle East & Africa

Key Points Covered in Systemic Inflammatory Response Syndrome Treatment Market Study:

• Growth of Systemic Inflammatory Response Syndrome Treatment in 2022
• Market Estimates and Forecasts (2017-2030)
•  Brand Share and Market Share Analysis
•  Key Drivers and Restraints Shaping Market Growth
•  Segment-wise, Country-wise, and Region-wise Analysis
•  Competition Mapping and Benchmarking
•  Recommendation on Key Winning Strategies
•  COVID-19 Impact on Demand for Systemic Inflammatory Response Syndrome Treatment and How to Navigate
•  Key Product Innovations and Regulatory Climate
•  Systemic Inflammatory Response Syndrome Treatment Consumption Analysis
•  Systemic Inflammatory Response Syndrome Treatment Production Analysis
•  Systemic Inflammatory Response Syndrome Treatment and Management